Replies to post #90 on Protalix BioTherapeutics Inc (PLX)

[DewDiligence]

I think the answer is 2018 or 2019 for Herceptin (depending on which of two similar patents pertains) and 2019 for Avastin. However, I caution that, unlike small molecules—where the FDA’s Orange Book tells you everything you need to know—determining the end of patent protection for a biologic is fraught with pitfalls because one cannot be certain as to which patents will be prosecuted by the branded-drug company. Regards, Dew